相似文献
1
Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected.
J Clin Invest. 2015 Sep;125(9):3356-64. doi: 10.1172/JCI80005. Epub 2015 Jul 13.
2
Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment.
Adv Cancer Res. 2015;128:95-139. doi: 10.1016/bs.acr.2015.04.002. Epub 2015 May 12.
3
Immunosuppressive cells and tumour microenvironment: focus on mesenchymal stem cells and myeloid derived suppressor cells.
Histol Histopathol. 2011 Jul;26(7):941-51. doi: 10.14670/HH-26.941.
4
MDSCs in cancer: Conceiving new prognostic and therapeutic targets.
Biochim Biophys Acta. 2016 Jan;1865(1):35-48. doi: 10.1016/j.bbcan.2015.08.001. Epub 2015 Aug 6.
5
Myeloid regulatory cells in tumor spreading and metastasis.
Immunobiology. 2015 Feb;220(2):236-42. doi: 10.1016/j.imbio.2014.07.017. Epub 2014 Jul 23.
6
Molecular Pathways: Targeting Tumor-Infiltrating Myeloid-Derived Suppressor Cells for Cancer Therapy.
Clin Cancer Res. 2015 Jul 15;21(14):3108-12. doi: 10.1158/1078-0432.CCR-14-2261. Epub 2015 May 12.
7
Myeloid-derived suppressor cell heterogeneity in human cancers.
Ann N Y Acad Sci. 2014 Jun;1319:47-65. doi: 10.1111/nyas.12469.
8
Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
Adv Exp Med Biol. 2020;1224:117-140. doi: 10.1007/978-3-030-35723-8_8.
9
The immunobiology of myeloid-derived suppressor cells in cancer.
Tumour Biol. 2016 Feb;37(2):1387-406. doi: 10.1007/s13277-015-4477-9. Epub 2015 Nov 26.
10
Myeloid cell heterogeneity in cancer: not a single cell alike.
Cell Immunol. 2018 Aug;330:188-201. doi: 10.1016/j.cellimm.2018.02.008. Epub 2018 Feb 14.
引用本文的文献
1
Cancer Immunotherapy in Combination with Radiotherapy and/or Chemotherapy: Mechanisms and Clinical Therapy.
MedComm (2020). 2025 Aug 31;6(9):e70346. doi: 10.1002/mco2.70346. eCollection 2025 Sep.
2
Understanding Tumor Dormancy: from Experimental Models to Mechanisms and Therapeutic Strategies.
Biomol Ther (Seoul). 2025 Sep 1;33(5):770-784. doi: 10.4062/biomolther.2025.056. Epub 2025 Aug 31.
3
Associations Between Myeloid-Derived Suppressor Cells, TIM-3+ T Cells, and Clinical Factors During the Post-transplant Neutropenia Period in Patients With Multiple Myeloma.
Cureus. 2025 Jun 24;17(6):e86641. doi: 10.7759/cureus.86641. eCollection 2025 Jun.
4
MicroRNAs in Cancer Immunology: Master Regulators of the Tumor Microenvironment and Immune Evasion, with Therapeutic Potential.
Cancers (Basel). 2025 Jun 27;17(13):2172. doi: 10.3390/cancers17132172.
5
Identification of anoikis-related subtypes and a risk score prognosis model, the association with TME landscapes and therapeutic responses in hepatocellular carcinoma.
Front Immunol. 2025 Jun 17;16:1602831. doi: 10.3389/fimmu.2025.1602831. eCollection 2025.
6
Dynamics of inflammatory signals within the tumor microenvironment.
World J Exp Med. 2025 Jun 20;15(2):102285. doi: 10.5493/wjem.v15.i2.102285.
7
Osteosarcoma immune microenvironment: cellular struggle and novel therapeutic insights.
Front Immunol. 2025 Jun 4;16:1584450. doi: 10.3389/fimmu.2025.1584450. eCollection 2025.
8
Adjuvant conditioning shapes the adaptive immune response promoting immunotolerance via NLRP3/interleukin-1.
iScience. 2025 May 13;28(6):112653. doi: 10.1016/j.isci.2025.112653. eCollection 2025 Jun 20.
9
Sex differences in bladder cancer: understanding biological and clinical implications.
Biol Sex Differ. 2025 May 13;16(1):31. doi: 10.1186/s13293-025-00715-6.
10
Characterizing the Emergence of Myeloid-Derived Suppressor Cell Subsets in a Murine Model of Pulmonary Fibrosis.
FASEB J. 2025 May 31;39(10):e70626. doi: 10.1096/fj.202500312RR.
本文引用的文献
1
Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.
J Exp Med. 2015 Mar 9;212(3):351-67. doi: 10.1084/jem.20140835. Epub 2015 Feb 9.
2
Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.
Clin Cancer Res. 2015 Jan 1;21(1):30-8. doi: 10.1158/1078-0432.CCR-14-1716.
3
Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells.
Oncotarget. 2014 Dec 15;5(23):12331-45. doi: 10.18632/oncotarget.2589.
4
Complexity and challenges in defining myeloid-derived suppressor cells.
Cytometry B Clin Cytom. 2015 Mar;88(2):77-91. doi: 10.1002/cyto.b.21206. Epub 2014 Dec 12.
5
Myeloid-derived suppressor activity is mediated by monocytic lineages maintained by continuous inhibition of extrinsic and intrinsic death pathways.
Immunity. 2014 Dec 18;41(6):947-59. doi: 10.1016/j.immuni.2014.10.020. Epub 2014 Dec 11.
6
A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
J Immunol Res. 2014;2014:659294. doi: 10.1155/2014/659294. Epub 2014 Nov 11.
7
Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
Cancer Immunol Immunother. 2015 Jan;64(1):1-13. doi: 10.1007/s00262-014-1639-3. Epub 2014 Nov 29.
8
Deficiency of Kruppel-like factor KLF4 in myeloid-derived suppressor cells inhibits tumor pulmonary metastasis in mice accompanied by decreased fibrocytes.
Oncogenesis. 2014 Nov 24;3(11):e129. doi: 10.1038/oncsis.2014.44.
9
Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.
J Clin Invest. 2014 Dec;124(12):5466-80. doi: 10.1172/JCI77053. Epub 2014 Nov 10.
10
Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
Clin Cancer Res. 2015 Jan 1;21(1):39-48. doi: 10.1158/1078-0432.CCR-14-1711. Epub 2014 Oct 15.
Zotero 插件